Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
The DOI matches its Crossref record; 16 of the 19 references it cites were found in a registry or an index.
Abstract
The synthetic opioid landscape continues to change as non-fentanyl-related substances appear in forensic toxicology casework. Among the newest synthetic opioids to emerge is isotonitazene, an analogue of a benzimidazole class of analgesic compounds. Isotonitazene is an active and potent synthetic opioid, but the extent to which this compound is causing toxicity among drug users was previously unknown. This report describes the confirmation and quantitation of isotonitazene in blood, urine and vitreous fluid through standard addition, as well as in vivo metabolic profile determination in drug users. Quantitative analysis was performed using liquid chromatography tandem mass spectrometry (LC–MS/MS), and metabolite discovery was performed using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). In total, 18 cases were confirmed positive for isotonitazene, nine of which were previously negative for any opioid. The average isotonitazene concentration in blood was 2.2 ± 2.1 ng/mL (median 1.75 ng/mL, range 0.4–9.5 ng/mL), and the average isotonitazene concentration in urine was 2.4 ± 1.4 ng/mL (median 2.7 ng/mL, range 0.6–4.0 ng/mL). The lowest concentration of isotonitazene in blood was 0.4 ng/mL (two cases) with no other opioids present; findings in death investigations. Four metabolites of isotonitazene were detected in vivo. N- and O-dealkylation products were determined to be the most prominent urinary biomarkers, while 5-amino-isotonitazene was identified in most blood samples. The prevalence and popularity of isotonitazene continue to increase in the United States in early 2020. Toxicologists, medical examiners and coroners should be aware of novel opioids outside the standard scope of testing, especially in medicolegal death investigations. Forensic scientists should add isotonitazene to testing procedures, and public health officials should counsel about potent new drugs and the dangers of opioid use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calello et al. [25] and Amaducci et al. [42,43] reported reversal doses ranging from 0.08 mg to 2.00 mg”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [25]
In the citing paper
“4‐Hydroxy nitazene has previously been hypothesised as a universal metabolite of nitazene analogues [8, 40].”
From Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries (2025) · cites this paper as [8]
Citations
Cites
(2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bkt054 · Cited by 873
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
Armenian, P., Vo, K. T., Barr-Walker, J., & Lynch, K. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.016 · Cited by 710 · cited 1×
“After its emergence, illicit fentanyl identifications in seized drug material increased, followed by diversification of the synthetic opioid drug market to include fentanyl analogues (2, 3) and non-fentanylrelated opioids such as U-47700 (4).”
BackgroundA review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J., & El-Haddad, S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.033 · Cited by 445
Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016
O’Donnell, J. K., Halpin, J., Mattson, C. L., Goldberger, B. A., & Gladden, R. M. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6643e1 · Cited by 387
Drug Overdose Deaths in the United States, 1999-2015.
Hedegaard, H. B., Warner, M., & Miniño, A. (2017) · PubMed · Cited by 299
A systematic approach to standard addition methods in instrumental analysis
Bader, M. (1980) · Journal of Chemical Education · doi:10.1021/ed057p703 · Cited by 293 · cited 1×
“A workflow by standard addition (4, 18, 19) was developed and validated for quantitative determination of isotonitazene by LC–MSMS.”
MethodMohr, A. L. A., Friscia, M., Papsun, D., Kacinko, S. L., Buzby, D., & Logan, B. K. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw086 · Cited by 199 · cited 4×
“A workflow by standard addition (4, 18, 19) was developed and validated for quantitative determination of isotonitazene by LC–MSMS.”
BackgroundMethodInfluentialSelf-citationThe Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union
Jannetto, P. J., Helander, A., Garg, U., Janis, G. C., Goldberger, B., & Ketha, H. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2017.281626 · Cited by 162
Blanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116
Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161116 · Cited by 103 · cited 1×
“Previously in the literature, several benzimidazole compounds (structural analogues of isotonitazene) were first reported as potential therapeutic agents in the 1950s, including metonitazene, etonitazene and clonitazene (Figure 1) (12, 13).”
Background
Research works printed but not linked: 4
- Drug Enforcement Administration, 2018, Schedules of Controlled Substances: Temporary Placement of Fentanyl-Related Substances in Schedule I
- Hoffmann, 1960, Benzimidazoles, United States Patent Office, 2, 935,514
- Krotulski, 2019, Isotonitazene
- Krotulski, 2019, Potent synthetic opioid—Isotonitazene—Recently identified in the Midwestern United States, NPS Discovery
Cited by
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141
Walton, S. E., Krotulski, A. J., & Logan, B. K. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab117 · Cited by 92
“by examining in vivo metabolism following the ingestion of isotonitazene based on the presence of the parent drug (Figure 1) (10).”
BackgroundSelf-citationKrotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91
Self-citationMontanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89
Mueller, F., Bogdal, C., Pfeiffer, B., Andrello, L., Ceschi, A., Thomas, A., & Grata, E. (2021) · Forensic Science International · doi:10.1016/j.forsciint.2021.110686 · Cited by 82
Old Drugs and New Challenges: A Narrative Review of Nitazenes
Pergolizzi Jr, J., Raffa, R., LeQuang, J. A. K., Breve, F., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.40736 · Cited by 81
“The European Monitoring Center for Drugs and Drug Addiction was first notified about the presence of isotonitazene in a biological sample obtained in July 2019 [15].”
BackgroundVandeputte, M. M., Krotulski, A. J., Walther, D., Glatfelter, G. C., Papsun, D., Walton, S. E., Logan, B. K., Baumann, M. H., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03276-4 · Cited by 80
Self-citationReports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero-Miller, J. D. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac023 · Cited by 68
Self-citationA Review on the Green Synthesis of Benzimidazole Derivatives and Their Pharmacological Activities
Nardi, M., Cano, N. C. H., Simeonov, S. P., Bence, R., Kurutos, A., Scarpelli, R., Wunderlin, D. A., & Procopio, A. (2023) · Catalysts · doi:10.3390/catal13020392 · Cited by 78
“…the original idea, wrote, and 4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl) ethyl)-1 H -benzo[d]imidazole) ( 54 , Figure 26), a novel member of the benzimidazole class of NPS opioids that structurally arises from cyclization of the two ethyl substituents of etonitazene to a pyrrolidine [252].”
BackgroundThe Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament
Vandeputte, M. M., Krotulski, A. J., Papsun, D. M., Logan, B. K., & Stove, C. P. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab082 · Cited by 71
Self-citationThe standard addition method and its validation in forensic toxicology
Hasegawa, K., Minakata, K., Suzuki, M., & Suzuki, O. (2021) · Forensic Toxicology · doi:10.1007/s11419-021-00585-8 · Cited by 70
In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances
Vandeputte, M. M., Cannaert, A., & Stove, C. P. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02855-7 · Cited by 65
De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03774-7 · Cited by 58
“N -Desethyl etonitazene and N -desethyl isotonitazene are metabolites of etonitazene and isotonitazene, respectively (Taoussi et al. 2024; Kanamori et al. 2024; Krotulski et al. 2020).”
BackgroundMethodInfluentialSelf-citationNon-Fentanyl New Synthetic Opioids—An Update
Zawilska, J. B., Adamowicz, P., Kurpeta, M., & Wojcieszak, J. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111775 · Cited by 55
U-47700 and Its Analogs: Non-Fentanyl Synthetic Opioids Impacting the Recreational Drug Market
Baumann, M. H., Tocco, G., Papsun, D. M., Mohr, A. L., Fogarty, M. F., & Krotulski, A. J. (2020) · Brain Sciences · doi:10.3390/brainsci10110895 · Cited by 52
Self-citationMu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53
“Isotonitazene has been found to undergo N- and O- dealkylation to create N-desalkyland O-desalkylisotonitazene species such as N-desethyl isotonitazene, and is also known to undergo reduction of the nitro group to produce 5-aminoisotonitazene; etonitazene and metonitazene have been found to produce similar metabolites…”
BackgroundGlatfelter, G. C., Vandeputte, M. M., Chen, L., Walther, D., Tsai, M.-H. M., Shi, L., Stove, C. P., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06451-2 · Cited by 52
“Isotonitazene exposures spread rapidly among individuals who use opioids, contributing to drug-related accidents and fatalities (EMCDDA 2020; Krotulski et al. 2020; Mueller et al. 2021; Shover et al. 2021).”
BackgroundPapsun, D. M., Krotulski, A. J., & Logan, B. K. (2022) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000787 · Cited by 51
Self-citationBarenholtz, E., Krotulski, A. J., Morris, P., Fitzgerald, N. D., Le, A., Papsun, D. M., Logan, B. K., Hahn, W. E., Goldberger, B. A., Cottler, L. B., et al. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103393 · Cited by 47
Self-citationDe Luca, M. A., Tocco, G., Mostallino, R., Laus, A., Caria, F., Musa, A., Pintori, N., Ucha, M., Poza, C., Ambrosio, E., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109263 · Cited by 48
Flualprazolam Blood Concentrations in 197 Forensic Investigation Cases
Papsun, D. M., Krotulski, A. J., Homan, J., Temporal, K. D. H., & Logan, B. K. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa070 · Cited by 46
Self-citationKrotulski, A. J., Papsun, D. M., Noble, C., Kacinko, S. L., & Logan, B. K. (2021) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14623 · Cited by 47
“Brorphine is a highly potent synthetic opioid that is increasing in prevalence in the Midwestern United States and other areas of the country.”
BackgroundMethodInfluentialSelf-citationEutylone Intoxications—An Emerging Synthetic Stimulant in Forensic Investigations
Krotulski, A. J., Papsun, D. M., Chronister, C. W., Homan, J., Crosby, M. M., Hoyer, J., Goldberger, B. A., & Logan, B. K. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa113 · Cited by 39
Self-citationFirst Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
Verougstraete, N., Vandeputte, M. M., Lyphout, C., Cannaert, A., Hulpia, F., Van Calenbergh, S., Verstraete, A. G., & Stove, C. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa094 · Cited by 44
“A few years ago, new synthetic opioids primarily encompassed analogs of the potent analgesic fentanyl, the latter having been associated with tens of thousands of deaths in the United States during the past few years (5–7).”
BackgroundVandeputte, M. M., Verougstraete, N., Walther, D., Glatfelter, G. C., Malfliet, J., Baumann, M. H., Verstraete, A. G., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03294-2 · Cited by 44
Fatal cases involving new psychoactive substances and trends in analytical techniques
Júnior, E. F., Leite, B. H. M., Gomes, E. B., Vieira, T. M., Sepulveda, P., & Caldas, E. D. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.1033733 · Cited by 49
“blood samples from 18 fatal cases, with only the opioid being detected in 9 cases (Krotulski et al., 2020b).”
BackgroundKozell, L. B., Eshleman, A. J., Wolfrum, K. M., Swanson, T. L., Bloom, S. H., Benware, S., Schmachtenberg, J. L., Schutzer, K. A., Schutzer, W. E., Janowsky, A., et al. (2024) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002052 · Cited by 42
Emerging Characteristics of Isotonitazene-Involved Overdose Deaths: A Case-Control Study
Shover, C. L., Falasinnu, T. O., Freedman, R. B., & Humphreys, K. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000775 · Cited by 37
“As observed in case reports, flualprazolam was present in most deaths involving isotonitazene.(6) Our findings suggest that this reflects co-use or codistribution of flualprazolam and isotonitazene, rather than rising background use, since flualprazolam was involved in only 8% of other synthetic opioid overdose deaths.”
MethodResultTaoussi, O., Berardinelli, D., Zaami, S., Tavoletta, F., Basile, G., Kronstrand, R., Auwärter, V., Busardò, F. P., & Carlier, J. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03735-0 · Cited by 40
“A different inclusion list was used for each analogue, based on in silico predictions (Supplementary Table S1) and postulation (Krotulski et al. 2020, 2021) (Table S2), but the same exclusion list was used, based on background ions.”
InfluentialBromazolam Blood Concentrations in Postmortem Cases—A British Columbia Perspective
Mérette, S. A. M., Thériault, S., Piramide, L. E. C., Davis, M. D., & Shapiro, A. M. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad005 · Cited by 40
Vandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39
Palmquist, K. B., Truver, M. T., Shoff, E. N., Krotulski, A. J., & Swortwood, M. J. (2023) · Journal of Forensic Sciences · doi:10.1111/1556-4029.15282 · Cited by 39
Self-citationBlanckaert, P., Balcaen, M., Vanhee, C., Risseeuw, M., Canfyn, M., Desmedt, B., Van Calenbergh, S., & Deconinck, E. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3113 · Cited by 39
Pucci, M., Singh Jutley, G., Looms, J., & Ford, L. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2309321 · Cited by 37
“In another study involving eighteen post-mortem cases, the median isotonitazene concentration in blood was 1.75 m g/L (range 0.4–9.5 m g/L) [18], very similar to the concentrations seen in our cohort.”
ResultInfluentialSchüller, M., Lucic, I., Øiestad, Å. M. L., Pedersen-Bjergaard, S., & Øiestad, E. L. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad071 · Cited by 37
“At present, such validated methods are limited; however, Wal-ton et al. (15) presented a validated quantitative approach for the simultaneous analysis of six nitazene analogs and three associated metabolites alongside the work by Krotulski et al. (16) for the quantification of isotonitazene.”
MethodVandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 36
Vandeputte, M. M., Glatfelter, G. C., Walther, D., Layle, N. K., St. Germaine, D. M., Ujváry, I., Iula, D. M., Baumann, M. H., & Stove, C. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107503 · Cited by 35
Walton, S. E., Krotulski, A. J., Glatfelter, G. C., Walther, D., Logan, B. K., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06292-5 · Cited by 33
Self-citationLukić, V., Micić, R. J., ARSIC, B. B., Nedović, B., & Radosavljević, Ž. (2021) · Open Chemistry · doi:10.1515/chem-2021-0196 · Cited by 40
“In vivo experiments show four metabolites identified using LC-QTOF-MS: Nand O-dealkylation products (N-desethyl-isotonitazene and N-desethyl-O-desalkyl-isotonitazene) were determined as urinary biomarkers, while 5-amino-isotonitazene was found in the majority of the investigated blood samples [430].”
BackgroundNon-fentanyl-derived synthetic opioids emerging during recent years
Hasegawa, K., Minakata, K., Suzuki, M., & Suzuki, O. (2022) · Forensic Toxicology · doi:10.1007/s11419-022-00624-y · Cited by 34
Nitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
“The median post-mortem isotonitazene concentration was between 1.2 µg/L and 1.7 µg/L (range: 0.4– 9.5 µg/L) and skewed toward the lower end of the range [11,26–28].”
InfluentialVerveri, C., Galletto, M., Massano, M., Alladio, E., Vincenti, M., & Salomone, A. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.115975 · Cited by 34
New Psychoactive Substances Intoxications and Fatalities during the COVID-19 Epidemic
Lo Faro, A., Berardinelli, D., Cassano, T., Dendramis, G., Montanari, E., Montana, A., Berretta, P., Zaami, S., Busardò, F., & Huestis, M. (2023) · Biology · doi:10.3390/biology12020273 · Cited by 33
“Etizolam and isotonitazene were also combined with fentanyl (n = 2) or flualprazolam [26] (n = 1).”
BackgroundInfluentialMetabolic characterization of the new benzimidazole synthetic opioids - nitazenes
Jadhav, G. R., & Fasinu, P. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434573 · Cited by 29
Pardi, J., Ford, S., & Cooper, G. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad062 · Cited by 29
Bade, R., Nadarajan, D., Hall, W., Brown, J. A., NPS Wastewater Consortium, & Schumann, J. (2025) · Addiction · doi:10.1111/add.70027 · Cited by 28
“Isotonitazene, the first to appear on the illicit drug market in 2019 after which it has come to dominate the NSO market, contributing to hundreds of fatalities in the United States (US) [8].”
Berardinelli, D., Taoussi, O., Carlier, J., Tini, A., Zaami, S., Sundermann, T., Busardò, F. P., & Auwärter, V. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1360 · Cited by 26
Siczek, M., Zawadzki, M., Siczek, M., Chłopaś-Konowałek, A., & Szpot, P. (2021) · Forensic Toxicology · doi:10.1007/s11419-020-00552-9 · Cited by 27
Kimani, M. M., Kern, S., Lanzarotta, A., Thatcher, M., Lorenz, L. M., Smith, S. W., Collins, M., Howe, G. W., & Wetherby, A. E. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3440 · Cited by 23
Calello, D. P., Aldy, K., Jefri, M., Nguyen, T.-A. T., Krotulski, A., Logan, B., Brent, J., Wax, P., Walton, S., Manini, A. F., et al. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2084406 · Cited by 26
Self-citationAmeline, A., Gheddar, L., Pichini, S., Stove, C., Aknouche, F., Maruejouls, C., Raul, J.-S., & Kintz, P. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119764 · Cited by 26
Advances in analytical methodologies for detecting novel psychoactive substances: a review
Krotulski, A. J., Mata, D. C., Smith, C. R., Palmquist, K. B., Modell, C., Vikingsson, S., & Truver, M. T. (2024) · Journal of Analytical Toxicology · doi:10.1093/jat/bkae098 · Cited by 30
Self-citationDe Baerdemaeker, K. S. C., Dines, A. M., Hudson, S., Sund, L. J., Waters, M. L., Hunter, L. J., Blundell, M. S., Archer, J. R. H., Wood, D. M., & Dargan, P. I. (2023) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcac039 · Cited by 21
Murari, M., Pesavento, S., Greco, F., Vettori, A., Tagliaro, F., & Gottardo, R. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3590 · Cited by 21
Menéndez-Quintanal, L. M., Matey, J. M., González, V. D. F., Serrano, B. B., Hernández-Díaz, F. J., Zapata, F., Montalvo, G., & García‐Ruiz, C. (2024) · Psychoactives · doi:10.3390/psychoactives3040033 · Cited by 23
Kurach, Ł., Chłopaś‐Konowałek, A., Budzyńska, B., Zawadzki, M., Szpot, P., & Boguszewska‐Czubara, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-03804-9 · Cited by 22
Fogarty, M. F., Vandeputte, M. M., Krotulski, A. J., Papsun, D. M., Walton, S. E., Stove, C. P., & Logan, B. K. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03257-7 · Cited by 23
Self-citationParks, C., Maskell, P., McKeown, D. A., & Couchman, L. (2024) · Journal of Analytical Toxicology · doi:10.1093/jat/bkae076 · Cited by 23
Isotonitazene, a synthetic opioid from an emerging family: The nitazenes
Bendjilali-Sabiani, J.-J., Eiden, C., Lestienne, M., Cherki, S., Gautre, D., den Broek, T. V., Mathieu, O., & Peyrière, H. (2024) · Therapies · doi:10.1016/j.therap.2024.05.004 · Cited by 21
Structural Characterization of Nitazene Analogs Using Electron Ionization-Mass Spectrometry (EI-MS)
Hardwick, E. K., & Tyler Davidson, J. (2024) · Forensic Chemistry · doi:10.1016/j.forc.2024.100605 · Cited by 20
The emergence of nitazenes: a new chapter in the synthetic opioid crisis
Caprari, C., Ferri, E., Rossetti, P., Gregori, A., Citti, C., & Cannazza, G. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04102-3 · Cited by 19
“Several authors (Parks et al. 2024; Walton et al. 2022; Krotulski et al. 2020, 2021; Pucci et al. 2024; Schüller et al. 2023; Diekhans et al. 2024; Pardi et al. 2023) have developed and validated quantitative methods to detect nitazene analogs with LODs and LOQs at a near or sub ng/mL.”
Curtis, B., Lawes, D. J., Caldicott, D., & McLeod, M. D. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3910 · Cited by 19
Vitrano, A., Giorgi, A. D., Abbate, V., Basile, G., Maida, N. L., Pichini, S., & Trana, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212332 · Cited by 19
Monti, M. C., De Vrieze, L. M., Vandeputte, M. M., Persson, M., Gréen, H., Stove, C. P., & Schlotterbeck, G. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116453 · Cited by 18
Walton, S. E., Stang, B. N., Kacinko, S. L., Papsun, D. M., Logan, B. K., & Krotulski, A. J. (2025) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaf040 · Cited by 17
Self-citationKanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3705 · Cited by 16
Interpol Review of Drug Analysis 2019-2022
Love, D., & Jones, N. S. (2023) · Forensic Science International Synergy · doi:10.1016/j.fsisyn.2022.100299 · Cited by 19
Gao, G., Yang, S., Wang, X., Xiang, P., Ma, L., Yan, F., & Shi, Y. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116707 · Cited by 16
Grigoryev, A., Kavanagh, P., Dowling, G., & Rodin, I. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac001 · Cited by 16
Identification of etazene (etodesnitazene) metabolites in human urine by LC‐HRMS
Verougstraete, N., Verhaeghe, A., Germonpré, J., Lebbinck, H., & Verstraete, A. G. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3377 · Cited by 15
Simão, A. Y., Antunes, M., Marques, H., Rosado, T., Soares, S., Gonçalves, J., Barroso, M., Andraus, M. H., & Gallardo, E. (2020) · Bioanalysis · doi:10.4155/bio-2020-0148 · Cited by 18
Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.-H., Ledochowski, S., Labat, L., Mégarbane, B., & Houzé, P. (2025) · Metabolites · doi:10.3390/metabo15060371 · Cited by 14
“Protonitazene and protonitazepyne were found in the ng/mL range in the plasma, consistent with previous reports [3,6,16].”
InfluentialWachełko, O., Tusiewicz, K., Szpot, P., & Zawadzki, M. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116796 · Cited by 14
Hardwick, E. K., & Davidson, J. T. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3921 · Cited by 14
Cannaert, A., Hulpia, F., Risseeuw, M., Uytfanghe, K. V., Deconinck, E., Calenbergh, S. V., Blanckaert, P., & Stove, C. P. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa066 · Cited by 14
Blood concentrations of new synthetic opioids
Adamowicz, P., & Nowak, K. (2021) · International Journal of Legal Medicine · doi:10.1007/s00414-021-02729-2 · Cited by 15
Zhao, K., Dai, Y., Wang, Y., Liu, J., Gu, J., Bai, H., Wurita, A., & Hasegawa, K. (2023) · Legal Medicine · doi:10.1016/j.legalmed.2023.102295 · Cited by 11
Liu, C., Huang, B., Hua, Z., Jia, W., & Zhi‐yu, L. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.10030 · Cited by 11
Volatile drug use and overdose during the first year of the COVID-19 pandemic in the United States
Schneider, K. E., Martin, E. M., Allen, S. T., Morris, M., Haney, K., Saloner, B. K., & Sherman, S. G. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104371 · Cited by 11
New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
Napoletano, S., Basile, G., Faro, A. F. L., & Negro, F. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i2.13008 · Cited by 12
Huang, B., Hua, Z., Liu, C., Li, J., Shu, J., & Li, Z. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3838 · Cited by 10
Zagorski, C. M., Myslinski, J. M., & Hill, L. G. (2020) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2020.102939 · Cited by 12
Interpol review of toxicology 2019–2022
Cheng, J. Y.-K., Hui, J. W.-S., Chan, W.-S., So, M., Hong, Y.-H., Leung, W.-T., Ku, K.-W., Yeung, H. S., Lo, K.-M., Fung, K.-M., et al. (2022) · Forensic Science International Synergy · doi:10.1016/j.fsisyn.2022.100303 · Cited by 12
“It was also suggested that N-desethyl-isotonitazene and N-desethyl-O-desalkyl-isotonitazene are the most appropriate metabolite biomarkers in urine, while 5-amino-isotonitazene was identified in most blood samples [199].”
Discriminative stimulus and antinociceptive effects of sixteen nitazene analogs in rodents
Gatch, M. B., Hill, R. D., Sundar, M., & Shetty, R. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110416 · Cited by 11
Evaluation of enzyme-linked immunosorbent assay screening kits for the detection of nitazene analogs
Pacana, A. L., & Skillman, B. N. (2025) · Journal of Forensic Sciences · doi:10.1111/1556-4029.70052 · Cited by 9
“The introduction of isotonitazene and brorphine to this market in 2019 marked the start of a transition to the use of opioids structurally dissimilar to opioids like oxycodone and fentanyl [ 4–6].”
The Future of Deadly Synthetic Opioids: Nitazenes and Their International Control
Lassi, N., & Jiang, S. (2025) · Global Policy · doi:10.1111/1758-5899.70000 · Cited by 9
Vandeputte, M. M., Walton, S. E., Shuda, S. A., Papsun, D. M., Krotulski, A. J., & Stove, C. P. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04722-7 · Cited by 10
“Quantitation of dipyanone was performed via liquid chromatography tandem quadrupole mass spectrometry (LCQQQ-MS) using the method of standard addition [47, 48].”
MethodSelf-citationA novel screening workflow for nitazene analogs using LC–MS/MS precursor ion scan acquisition
Pacana, A. L., & Skillman, B. N. (2025) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaf046 · Cited by 8
Post‐Mortem Identification and Toxicological Findings of Fluetonitazepyne and Isotonitazepyne
Kriikku, P., Pelander, A., Jylhä, A., & Ojanperä, I. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3928 · Cited by 8
Fogarty, M. F., Mohr, A. L. A., Papsun, D. M., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa180 · Cited by 8
Self-citationBallotari, M., Pigaiani, N., Bacci, A., Scott, K. S., Davis, G. G., Gottardo, R., & Bortolotti, F. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3852 · Cited by 7
“From July 2019 and during the COVID-19 pandemic (early 2020), substances included in the nitazenes opioid class, including isotonitazene and metonitazene, were identified for the first time in Europe and North America in the street drug supply and toxicological samples [6, 7].”
Nalakath, J., Thacholil, R. P., Kadry, A., P, S., & Praseen, O. K. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9982 · Cited by 6
Phelps, C., Hardwick, E. K., Couch, A. N., & Davidson, J. T. (2025) · Journal of Forensic Sciences · doi:10.1111/1556-4029.70084 · Cited by 6
Isotonitazene: a new synthetic opioid in the UK
Nahar, L. K., Andrews, R., & Paterson, S. (2021) · BMJ · doi:10.1136/bmj.n3143 · Cited by 6
Berardinelli, D., Taoussi, O., Ovat, D. Y., Pichini, S., Pulver, B., Auwärter, V., Busardò, F. P., Basile, G., Laudadio, E., & Carlier, J. (2026) · Archives of Toxicology · doi:10.1007/s00204-025-04163-4 · Cited by 5
Ferreira, C. F., Antunes, A. M. M., Gaspar, H., & Caldeira, M. J. (2025) · Forensic Chemistry · doi:10.1016/j.forc.2025.100696 · Cited by 5
Zhang, M., Feng, J., Chen, H., Xiang, P., Yan, H. F., & Zhao, J. (2025) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaf099 · Cited by 5
Bendjilali-Sabiani, J.-J., Eiden, C., Lossois, M., Martrille, L., Peyrière, H., & Mathieu, O. (2025) · Forensic Science International · doi:10.1016/j.forsciint.2025.112763 · Cited by 6
Brorphine and Its Analogues: Pharmacology, Toxicology, and Biomonitoring
Marchei, E., Graziano, S., Pichini, S., & Farré, M. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001446 · Cited by 6
Metadata
- Authors
- Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K.
- Affiliations
- Fredric Rieders Family Foundation (US)
- Toxicology Department, NMS Labs, 200 Welsh Rd, Horsham, PA 19044, USA
- Corresponding author
- Krotulski, Alex J
- Venue
- Journal of Analytical Toxicology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-24
- Volume
- 44
- Issue
- 6
- Pages
- 521-530
- ISSN
- 0146-4760 (ISSN-L)
- 1945-2403
- OpenAlex
- W3008681705
- Semantic Scholar
- 448a39d2cd5a8a4e27357b13f5b56754e7582dcf
- Cited by
- 146
- References
- 19
- Citations by year
- 2026: 25 · 2025: 34 · 2024: 21 · 2023: 20 · 2022: 19 · 2021: 15 · 2020: 12
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Analytical Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Historical and Scientific Studies
- Keywords
- isotonitazene, synthetic opioids, opioid metabolites, dealkylation, urinary biomarkers, vitreous fluid, death investigation, drug users, new psychoactive substances
- MeSH terms
- Analgesics, Opioid, Benzimidazoles, Illicit Drugs, Designer Drugs, Substance Abuse Detection, Forensic Toxicology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.